198 related articles for article (PubMed ID: 30093131)
1. Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting.
Boye KS; Mody R; Wu J; Lage MJ; Botros FT; Woodward B
Clin Ther; 2018 Aug; 40(8):1396-1407. PubMed ID: 30093131
[TBL] [Abstract][Full Text] [Related]
2. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024
[TBL] [Abstract][Full Text] [Related]
3. Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.
Fuechtenbusch M; Aberle J; Heitmann E; Nicolay C; Jung H
Diabetes Obes Metab; 2019 Jun; 21(6):1340-1348. PubMed ID: 30737891
[TBL] [Abstract][Full Text] [Related]
4. Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.
Tuttle KR; McKinney TD; Davidson JA; Anglin G; Harper KD; Botros FT
Diabetes Obes Metab; 2017 Mar; 19(3):436-441. PubMed ID: 27766728
[TBL] [Abstract][Full Text] [Related]
5. Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7).
Tuttle KR; Lakshmanan MC; Rayner B; Zimmermann AG; Woodward B; Botros FT
Diabetes Obes Metab; 2019 Jun; 21(6):1493-1497. PubMed ID: 30762290
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes.
Kaneko S; Oura T; Matsui A; Shingaki T; Takeuchi M
Endocr J; 2017 Dec; 64(12):1165-1172. PubMed ID: 28904247
[TBL] [Abstract][Full Text] [Related]
7. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.
Ishii H; Madin-Warburton M; Strizek A; Thornton-Jones L; Suzuki S
J Med Econ; 2018 May; 21(5):488-496. PubMed ID: 29357718
[TBL] [Abstract][Full Text] [Related]
9. Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.
Giorgino F; Yu M; Haupt A; Milicevic Z; García-Pérez LE
Diabetes Obes Metab; 2019 Nov; 21(11):2570-2575. PubMed ID: 31364266
[TBL] [Abstract][Full Text] [Related]
10. The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes.
Inagaki N; Araki E; Oura T; Matsui A; Takeuchi M; Tanizawa Y
Diabetes Obes Metab; 2016 Dec; 18(12):1279-1282. PubMed ID: 27488246
[TBL] [Abstract][Full Text] [Related]
11. Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.
Mody R; Huang Q; Yu M; Patel H; Zhang X; Wang L; Grabner M
BMJ Open Diabetes Res Care; 2019; 7(1):e000884. PubMed ID: 31875137
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis.
Xu J; Yao D; Xia J
J Clin Pharm Ther; 2021 Oct; 46(5):1245-1253. PubMed ID: 33675117
[TBL] [Abstract][Full Text] [Related]
13. Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results.
Mody R; Yu M; Grabner M; Boye K; Teng CC; Kwan AYM
Clin Ther; 2020 Nov; 42(11):2184-2195. PubMed ID: 33256915
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.
Suzuki S; Oura T; Takeuchi M; Boye KS
Health Qual Life Outcomes; 2017 Jun; 15(1):123. PubMed ID: 28606095
[TBL] [Abstract][Full Text] [Related]
15. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.
Blonde L; Jendle J; Gross J; Woo V; Jiang H; Fahrbach JL; Milicevic Z
Lancet; 2015 May; 385(9982):2057-66. PubMed ID: 26009229
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis.
Chang KC; Shao SC; Kuo S; Yang CY; Chen HY; Chan YY; Ou HT
Cardiovasc Diabetol; 2020 Oct; 19(1):172. PubMed ID: 33036617
[TBL] [Abstract][Full Text] [Related]
17. Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide.
Umpierrez G; Pantalone KM; Atisso CM; Landó LF; Patel H
Diabetes Obes Metab; 2019 Jun; 21(6):1365-1372. PubMed ID: 30756511
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9).
Yu M; Brunt KV; Milicevic Z; Varnado O; Boye KS
Clin Ther; 2017 Nov; 39(11):2284-2295. PubMed ID: 29110972
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.
Wang W; Nevárez L; Filippova E; Song KH; Tao B; Gu L; Wang F; Li P; Yang J
Diabetes Obes Metab; 2019 Feb; 21(2):234-243. PubMed ID: 30129089
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial.
Wang W; Yan X; Cheng Z; Zhang Q; Wang R; Deng Y; Ma J; Zhu D
Diabetes Obes Metab; 2023 Dec; 25(12):3690-3699. PubMed ID: 37732487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]